For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

Regeneron and Sanofi’s Dupixent trial shows major improvement in allergic fungal rhinosinusitis symptoms in patients 6+. Read ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal ...

The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...

A systematic review reports that monoclonal antibodies and JAK inhibitors can be effective in the treatment and clearance of ...

Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI.

A study has found that people with eczema are able to bathe either daily or weekly, without any impact on their symptoms.

Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary and ...

Sarah Bradley is a writer with six years of experience creating personal essays, reported features, and content related to health and parenting topics. William Truswell, MD, FACS, operates his own ...